|
|
Line 138: |
Line 138: |
| .nav { | | .nav { |
| position:relative; | | position:relative; |
− | width: 101%; | + | width: 103%; |
| text-align: center; | | text-align: center; |
| } | | } |
Line 462: |
Line 462: |
| display: block; | | display: block; |
| } | | } |
− | .tit:hover {
| |
− | text-decoration: underline;
| |
− | }
| |
− | .Ltit {
| |
− | font-size: 18px;
| |
− | margin-bottom: 20px;
| |
− | width: 80%;
| |
− | margin-left: auto;
| |
− | margin-right: auto;
| |
− | color: black;
| |
− | margin-top: 20px;
| |
− | }
| |
− | .detail {
| |
− | width: 72.5%;
| |
− | margin-left: auto;
| |
− | margin-right: auto;
| |
− | font-size: 17px;
| |
− | margin-bottom: 20px;
| |
− |
| |
− |
| |
− | line-height: 25px;
| |
− | text-indent: 1.5em;
| |
− | text-align: justify;
| |
− | word-spacing: 4px;
| |
− | letter-spacing: 1px;
| |
− | }
| |
− | .squ {
| |
− | width: 100%;
| |
− | }
| |
− | img {
| |
− | width: 45%;
| |
− | margin-left: auto;
| |
− | margin-right: auto;
| |
− | display: block;
| |
− | margin-top: 20px;
| |
− | margin-bottom: 15px;
| |
− | }
| |
− | .blue {
| |
− | color: blue;
| |
− | font-size: 16px;
| |
− | font-weight: 900;
| |
− | }
| |
− | #twi1,#twi2 {
| |
− | width: 35%;
| |
− | display: inline-block;
| |
− | float: left;
| |
− | }
| |
− | #twi1 {
| |
− | margin-left: 13%;
| |
− | }
| |
− | #twi2 {
| |
− | margin-left: 3%;
| |
− | }
| |
− | </style>
| |
− | </head>
| |
− | <body>
| |
− | <div class="nav">
| |
− | <li style="width:10%;"><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li>
| |
− | <li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B">Home</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Project</a>
| |
− | <ul class="ultop">
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Overview</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Propoptosis">Apoptosis Induction</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protumor">Tumor specific promoter</a></li>
| |
− | </ul>
| |
− | </li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Achievements</a>
| |
− | <ul class="ultop">
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Results</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Parts">Parts</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Judging">Judging</a></li>
| |
− | </ul>
| |
− | </li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Modeling">Modeling</a>
| |
− | <ul class="ultop">
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Apoptosis">Apoptosis</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Crispri">CRISPRi/a</a></li>
| |
− | </ul>
| |
− | </li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Notebook</a>
| |
− | <ul class="ultop">
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Protocol</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Safety">Safety</a></li>
| |
− | </ul>
| |
− | </li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Human Practice</a>
| |
− | <ul class="ultop">
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Overview</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP1">Project Design</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP2">Public Outreach</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP3">Hospice Care</a></li>
| |
− | </ul>
| |
− | </li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Lab</a>
| |
− | <ul class="ultop">
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Team</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Collaborations">Collaborations</a></li>
| |
− | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Attributions">Attributions</a></li>
| |
− | </ul>
| |
− | </li>
| |
− | </div>
| |
− | <div class="space"></div>
| |
− | <div class="titleName red">PART ONE, project design: A search for a better cure</div>
| |
− | <p class="tit red" style="width: 11%;margin-left: auto;margin-right: auto;display: block;text-decoration: none;font-size: 32px;">Summary</p>
| |
− | <div class="summary" style="margin-top:20px;">
| |
− | We always endeavored to combine our work in laboratory with human practice. In our minds human practice should be interspersed in our experiment; experiment and human practice were combined together and promoting each other. Here is how our human work in the whole process of our project.
| |
− | </div>
| |
− | <img src="../img/photo/pd.png" style="width: 60%;">
| |
− | <p class="tit red" style="width: 50%;margin-left: auto;margin-right: auto;display: block;margin-top: -90px;text-decoration: none;font-size: 32px;">how did we come up with the idea</p>
| |
− |
| |
− |
| |
− | <div class="squ" style="margin-top: 40px;">
| |
− | <p class="tit red" id="p0">(1)Seminar for Young Scientist on Lung Cancer</p>
| |
− | <div id="squ0">
| |
− | <img src="https://static.igem.org/mediawiki/parts/4/45/Wiki_photo_a.jpg">
| |
− | <img src="https://static.igem.org/mediawiki/parts/c/c7/Wiki_photo_aa.png">
| |
− | <p class="detail">It was in the Seminar for Young Scientist on Lung Cancer that we first get interested in cancer and tumour. Here we learnt about cancer staging and different types of cancers especially lung cancer so after the seminar we searched for more information through the internet and read literatures about it. Finally we decided the theme of our iGEM project is “the treatment of adenocarcinoma of lung”.</p>
| |
− | </div>
| |
− | </div>
| |
− |
| |
− | <div class="squ">
| |
− | <li class="tit red" id="p1">(2) Seminar about Progress on Treatment of Terminal NSCLC.</li>
| |
− | <div id="squ1">
| |
− | <img src="https://static.igem.org/mediawiki/parts/5/5c/Wiki_photo_b.jpg">
| |
− | <p class="detail">In Seminar about Progress on Treatment of Terminal NSCLC, we learnt that the biggest problem in treating lung cancer was cancer cell proliferation. When cancer cell begin to proliferate, it is much harder to identify and kill the cancer cells so we assumed a treatment which can recognize and kill cancer cells with no harm to normal cells. According to literatures, we learnt that adjusting the ratio of two genes named Bcl-2 and bax can induce the apoptosis of lung cancer cells without doing harm to other cells. Here we were able to set up our research direction and make a great progress in our project.</p>
| |
− | </div>
| |
− | </div>
| |
− |
| |
− | <div class="squ">
| |
− | <p class="tit red" id="p2">(3)current therapy for cancer----a visit to tumour hospital</p>
| |
− | <div id="squ2">
| |
− | <img src="https://static.igem.org/mediawiki/parts/4/49/Wiki_photo_c.jpg">
| |
− | <p class="detail">Interview with Dr Huang Yuanyuan: On July 17,we interviewed Dr Huang Yuanyuan from Tumour Hospital of Sun Yat Sen University. During the interview Dr Huang told us that for the first step of treating adenocarcinoma of lung patients are usually asked to have a gene analysis to let doctors be able to know the patients’ condition. The gene analysis is usually an analysis of receptor EGFR and this can help doctors to make a choice of treatments and drugs. Nowadays we have molecular targeted therapy, immunotherapy, chemotherapy, radiotherapy and operation for treating cancer. Molecular targeted therapy is the most widely used therapy which is quite useful but it still facing problems like drug resistance so we have to apply different drugs and therapies to avoid that. She told us that if gene targeted therapy can be put into clinic, there would be no resistance to drug. She said that gene targeted therapy had a bright future.She also mentioned that CRISPR/Cas9 was a very useful tool in gene targeted therapy which was easy to be standardized and modularised. This was quiet corresponded with the idea of synthetic biology. The interview reminded us that we could use CRIPR/Cas9 technology to regulate and control bcl-2 and bax. After the interview we had a more specific idea of our project.</p>
| |
− | </div>
| |
− | </div>
| |
− |
| |
− | <div class="squ">
| |
− | <p class="tit red" id="p3">(4)advice from experts(interview DR.CAI)</p>
| |
− | <div id="squ3">
| |
− | <img src="https://static.igem.org/mediawiki/parts/d/de/Wiki_photo_d.jpg">
| |
− | <p class="detail">Interview with Dr Cai Xiuyu: On July 17,we interviewed to Dr Cai Xiuyu from Tumour Hospital of Sun Yat Sen University, after we told him about our project he told is that safety and effectiveness was most considered by doctors when choosing a therapy of tumour and safety was even more important than effectiveness. He told us that there were different kinds of targeted drug for tumour like TKI which are small molecules able to get in a cell, and AKT which can hinder the energy metabolism of cancer cells and antibodies .etc. He said that because of its complication, gene therapy had not yet been put into clinic but it was a hopeful therapy in theory and there is still a long way to go. He was confident to our project and hoped that we could succeed with our project and solve the problems modern clinical treatment of cancer. The interview reminded us to pay attention to the safety and effectiveness of our therapy. So we decided to put tumour specific promoter surivin and synthetic promoter bax promoter into use. Problem of safety was solved by the specificity of surivin and effectiveness was ensured by scaling effect of bax promoter. This change perfected our project.</p>
| |
− | </div>
| |
− | </div>
| |
− |
| |
− | <div class="squ">
| |
− | <p class="tit red" id="p4">(5)CCIA Sun-Yat-Sen University Workshop----A Brain Storm</p>
| |
− | <div id="squ4">
| |
− | <img src="https://static.igem.org/mediawiki/parts/d/d7/Wiki_photo_e.jpg">
| |
− | <img src="https://static.igem.org/mediawiki/parts/8/89/Wiki_photo_ee.png">
| |
− |
| |
− | <p class="detail">CCIA Sun Yat Sen University Workshop was held for iGEM teams from different universities,in China. Teams had chances to show their projects and share experiences with other teams. The workshop had a similar process compared to the official process of iGEM competition so this workshop was also a rehearsal for us before the final competition. So we treated the workshop as the real competition and had full preparation for the presentation. It was also a brain storm among the 28 teams that attended to the workshop. Here we came with many new ideas and also received lots of helpful advice.</p>
| |
− | <p class="detail">Here is some of the advice we have got.</p>
| |
− | <p style="margin-left:auto;margin-right:auto;display:block;width: 30%;color:#d6515c;margin-bottom: 40px;font-size:36px;margin-top:50px;"><span>For human practice</span></p>
| |
− | <p class="detail">As a part of the workshop, different teams in the workshop had a chance to show their posters. As the one in charge of human practice in our team, I seized this chance to have a communication with students from Third Military Medical University. As a part of their human practice, they had cooperation with a primary school to let pupils colour cartoons about synthetic biology as an intertesting game of their school sports. As students from medical university who lucubrated in medicine, they gave treasured suggestion to us after knowing that our project was about adenocarcinoma of lung. They suggested that human practice as an extension of our project on humanity aspect should focus on patients in tumour hospitals. They believed that it would be better for us if we paid attention on patients with different cancers rather than merely on patients of adenocarcinoma of lung. They advised us to process a research about patients’ attitude towards modern treatments for cancer like chemotherapy and their prize as well as their expectation to their treatments. Some of the patients were unwilling to suffer the painful treatments while others cannot afford expensive expense of cancer therapy. Some want their illness to be totally cured while others only expect to live longer. As for gene therapy that we worked on they said it was important to know the patients’ attitude about it, because the new therapy still had ethical problems and not all people can accept it. They told us understand of patients’ need and drawback of modern treatments was very important for our promotion of the project and the application of gene therapy in the future so we needed to fully communicate to patients.</p>
| |
− | <img src="../img/photo/ff.png">
| |
− | <p style="margin-left:auto;margin-right:auto;display:block;width: 30%;color:#d6515c;margin-bottom: 40px;font-size:36px;margin-top:50px;"><span>For our presentation:</span></p>
| |
− | <p class="detail"> Our presentation was appreciated by Professor Zhang Jun and he was glad to see we made progress with our project. He also gave us treasured suggestion to our presentation. He said we needed a good data analysis, a clear diagram for data and results, and our presentation slides should be consistent and having a suitable typeface. He emphasized that we should ensure that there are no mistakes in our slides by the time we make the presentation. He advised us to make a good use of the time to check our presentation and slides before the presentation on the real competition. He sent us the best wish that our presentation could successfully show the significance of our project to the judges.</p>
| |
− | </div>
| |
− | </div>
| |
− |
| |
− | <div class="squ">
| |
− | <p class="tit red" id="p5">(6)Sino-USA Chinese Collaboration Workshop:Some fair advice for improvement.</p>
| |
− | <div id="squ5">
| |
− |
| |
− | <img src="../img/photo/gg.png">
| |
− | <p class="detail">It was very fortunate for us to meet professor Qi Lei in Sino-USA Chinese Collaboration Workshop and he gave very helpful advice to our research. When we designed our experiment we planned to target downstream gene bcl-2 with dcas9 and vp64 in order to inhibit the expression of bcl-2. Professor Qi pointed out that it was different between mammal’s cells and yeast’s or prokaryotic cells.He told us that it was very likely that we found the inhibition we expected appeared in yeast’s cells but found nothing in mammal’s cells. With his suggestion we decided to choose another method.</p>
| |
− |
| |
− | </div>
| |
− | </div>
| |
− |
| |
− | <div class="squ" style="padding-bottom: 40px;">
| |
− | <p class="tit red" id="p6">(7)law and regulation</p>
| |
− | <div id="squ6">
| |
− |
| |
− | <img src="https://static.igem.org/mediawiki/parts/1/19/Wiki_photo_g.jpg" id="twi1">
| |
− | <img src="https://static.igem.org/mediawiki/parts/b/b4/Wiki_photo_gg.png" id="twi2">
| |
− | <p class="detail">Interviewing associate professor Zhou Shiwen:</p>
| |
− | <p class="detail">Associate Professor Zhou Shiwen from school of law of SCUT is a member of Life ethics and biological safety review committee of BGI. These years she is working on laws about gene resource conservation. In December 2015 our members Yang Yanxia and Lin Ziyuan interviewed Associate Professor Zhou Shiwen for information about laws on gene technology and biosafety.</p>
| |
− | <p class="detail">In the interview she told us three main problems that we needed to pay attention to:</p>
| |
− | <p class="detail">(1)Lab operating:Laboratory should be regularly sterilized with UV lights and benches need to be cleaned with alcohol before and after used. Gloves and masks should be worn during experiments.</p>
| |
− | <p class="detail">(2)Awareness of biosafety:Experiments should be operated in sterile environment and pollution of germs should be avoided, for example using biosafety cabinets in dealing with infectious materials.</p>
| |
− | <p class="detail">(3)Bioethics: Bioethics should be considered in zoopery. Animals like mice need to be well treated after our experiment, like providing proper medical treatments or operating euthanasia for dying one.</p>
| |
− | </div>
| |
− |
| |
− |
| |
− |
| |
− |
| |
− | </body>
| |
− | <script>
| |
− | window.onload = function() {
| |
− |
| |
− | var ht = new Array();
| |
− |
| |
− |
| |
− | var node = document.getElementsByClassName("squ").length;
| |
− |
| |
− | for(i = 0;i < node;i++){
| |
− | ht[i] = document.getElementById('squ' + i).innerHTML;
| |
− | document.getElementById('squ' + i).innerHTML = '';
| |
− | }
| |
− |
| |
− | for(i = 0;i < node;i++){
| |
− |
| |
− | (function (){
| |
− | var j = i;
| |
− | document.getElementById('p' + j).addEventListener('click',function() {
| |
− | if(document.getElementById('squ' + j).innerHTML) {
| |
− | document.getElementById('squ' + j).innerHTML = '';
| |
− | } else {
| |
− | document.getElementById('squ' + j).innerHTML = ht[j];
| |
− | }
| |
− |
| |
− | });
| |
− | })();
| |
− |
| |
− | }
| |
− | }
| |
− |
| |
− | </script>
| |
− | </html>
| |